



DATE: May 30, 2002 SHEET 1 of 1

TECH CENTER 1600/2900

JUN 06 2002

RECEIVED

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6791.US.02

SERIAL NO.

10/081,207

APPLICANT(S)

M. Cowart *et al.*

FILING DATE

February 25, 2002

GROUP ART NO.

1642

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
VB	A1	US 4,297,369	10/27/1981	Takizawa <i>et al.</i>	424	285	07/28/1980
M	A2	US 4,447,620	05/08/1984	Sih <i>et al.</i>	548	336	10/12/1982
M	A3	US 4,452,986	06/05/1984	Johnson <i>et al.</i>	548	336	09/30/1982
M	A4	US 5,648,372	07/15/1997	Naito <i>et al.</i>	514	383	02/01/1995
HA							
HA							

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION	
							YES	NO
M	B1	0 169 012 A1	22.01.1986	EP				
M	B2	94/26738	24.11.1994	WO				
M	B3	0 978 512 A1	09.02.2000	EP				
M	B4	00/06254	10.02.2000	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

M	C1	LEURS, R., <i>et al.</i> "Therapeutic potential of histamine H ₃ receptor agonists and antagonists", Trends in Pharmacological Sciences 1998, Vol. 19 (5), pp. 177-183 (May 1998)
M	C2	HAAS, H., <i>et al.</i> "Subcortical modulation of synaptic plasticity in the hippocampus", Behavioural Brain Research, Germany, Vol. 66, pp. 41-44 (Jan. 1995)
CH	C3	SCHWARTZ, J., <i>et al.</i> "Histaminergic transmission in the mammalian brain", Physiological Reviews, France, Vol. 71, No. 1, pp. 1-51 (Jan. 1991)

EXAMINER

V. Balasubramaniam

DATE CONSIDERED

6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

#5

DATE March 19, 2003 SHEET 1 of 1

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6791.US.02

SERIAL NO.

10/081,207

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S)


Coward, et al.

FILING DATE

February 22, 2002

MAR 26 2003

1624

RECEIVED
MAR 26 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
VB	A1	3,903,092	09/02/1975	Chapman et al.	260	293	10/24/1972
IM	A2	3,910,955	10/07/1975	Chapman et al.	260	330	06/18/1973
IM	A3	4,237,144	12/02/1980	Cragoe et al.	424	270	06/21/1979
IM	A4	4,495,357	01/22/1985	Johnson	546	269	09/30/1982
IM	A5	5,436,246	07/25/1995	Bernotas et al.	514	255	09/15/1993
IM	A6	5,747,508	05/05/1998	Richter et al.	514	320	12/06/1996
IM	A7	5,858,995	01/12/1999	Kawai et al.	514	100	
IM	A8	6,302,837	10/16/1901	De Nanteuil et al.	574	337	10/13/2000

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
IM	B1	0 512 570	11.10.1995	EP			
IM	B2	0 982 300	01.03.2000	EP			
IM	B3	01/23380	05.04.2001	WO			
IM	B4	02/10156	07.02.2002	WO			
IM	B5	95/04052	09.02.1995	WO			
IM	B6	95/29907	09.11.1995	WO			
IM	B7	96/11192	18.04.1996	WO			
IM	B8	98/38188	03.09.1998	WO			
IM	B9	98/52946	26.11.1998	WO			
IM	B10	99/61435	02.12.1999	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

IM	C1	Descamps et al., "Benzofurans. XLII. Synthesis of 2-benzofurylmethylamines and amides of coumarilic acids," Chimica terapeutica 5(3):169-184 (1970)
IM	C2	JP 07173158 Abstracts

EXAMINER


V. Balasubraman

DATE CONSIDERED

6/28/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



DATE: April 14, 2004

SHEET 1 of 3

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6791US02

SERIAL NO.

10/081,207

APPLICANT(S)

Cowart, et al.

FILING DATE

February 25, 2002

GROUP

1624

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

M	C1	Bjenning et al., "Peripherally Administered Ciproxifan Elevates Hypothalamic Histamine Levels And Potently Reduces Food Intake in the Sprague Dawley Rat," Histamine Research In The New Millennium, Proceedings Of The International Sendai Histamine Symposium Held In Sendai, Japan, 22-25 November 2000, p. 449-450
M	C2	De Almeida et al., "Memory Facilitation by Histamine," Arch. Int. Pharmacodyn., 283:193-198 (1986).
M	C3	Delaunois et al., "Modulation Of Acetylcholine, Capsaicin and Substance P Effects by Histamine H ₃ Receptors in Isolated Perfused Rabbit Lungs," European Journal Of Pharmacology, 277:243-250 (1995).
M	C4	Dimitriadou et al., "Functional Relationship Between Mast Cells and C-Sensitive Nerve Fibres Evidenced by Histamine H ₃ -Receptor Modulation in Rat Lung and Spleen," Clinical Science, 87:151-163 (1994).
M	C5	Duméry et al., "Development of Amygdaloid Cholinergic Mediation of Passive Avoidance Learning in the Rat," Exp. Brain. Res., 67:61-69 (1987).
M	C6	Ellingboe et al., "Antihyperglycemic Activity of Novel Naphthalenyl 3H-1,2,3,5-Oxathiadiazole 2-Oxides," J. Med. Chem. 36:2485-2493 (1993)
M	C7	Fitzsimons et al., "Histamine Receptors Signalling in Epidermal Tumor Cell Lines With H-ras Gene Alterations," Inflamm. Res., 47, Supplement 1, S50-S51 (1998).
M	C8	Haas et al., Subcortical Modulation of Synaptic Plasticity in the Hippocampus," Behavioural Brain Research, 66:41-44 (1995).
M	C9	Hatta et al., "Activation of Histamine H ₃ Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Prolonged Myocardial Ischemia ^{1,2} ," The Journal Of Pharmacology And Experimental Therapeutics, 283(2):494-500 (1997).
M	C10	Imamura et al., "Activation Of Histamine H ₃ -Receptors Inhibits Carrier-Mediated Norepinephrine Release During Prolonged Myocardial Ischemia," Circulation Research, 78(3):475-481 (1996).
M	C21	Imamura et al., "Histamine H ₃ -Receptor-Mediated Inhibition Of Calcitonin Gene-Related Peptide Release From Cardiac C Fibers," Circulation Research, 78(5):863-869 (1996).



	C14	Kamei et al., "Participation Of Histamine In The Step-Through Active Avoidance Response And Its Inhibition By H ₁ -Blockers," Japan J. Pharmacol., 57:473-482 (1991).
	C15	Leurs et al., "The Histamine H ₃ -Receptor: A Target For Developing New Drugs," Progress In Drug Research, 39:127-165 (1992).
M	C16	Leurs et al., "The Medicinal Chemistry And Therapeutic Potentials Of Ligands Of The Histamine H ₃ Receptor," Progress In Drug Research, 45:107-165 (1995).
M	C17	Leurs et al., "Therapeutic Potential Of Histamine H ₃ Receptor Agonists And Antagonists," Trends In Pharm. Sci, 19:177-183 (1998).
M	C18	Levi et al., "Histamine H ₃ -Receptors: A New Frontier In Myocardial Ischemia," The Journal Of Pharmacology And Experimental Therapeutics, 292(3):825-830 (2000).
M	C19	Lin et al., "Involvement Of Histaminergic Neurons In Arousal Mechanisms Demonstrated With H ₃ -Receptor Ligands In The Cat," Brain Research, 523:325-330 (1990).
M	C20	Matsubara et al., "UK-14,304, R(-) α -Methyl-Histamine And SMS 201-995 Block Plasma Protein Leakage Within Dura Mater By Prejunctional Mechanisms," European Journal Of Pharmacology, 224:145-150 (1992).
M	C21	Mazurkiewicz-Kwilecki et al., "Changes In The Regional Brain Histamine And Histidine Levels In Postmortem Brains Of Alzheimer Patients," Can. J. Physiol. Pharmacol, 67: 75-78 (1989).
M	C22	McLeod et al., "Histamine H ₃ Antagonists," Progress In Resp. Research 31:133-134 (2001)
M	C23	Monti et al., "Effects Of Selective Activation Or Blockade Of The Histamine H ₃ Receptor On Sleep And Wakefulness," European Journal Of Pharmacology, 205:283-287 (1991).
M	C24	Monti et al., "Sleep And Waking During Acute Histamine H ₃ Agonist BP2.94 Or H ₃ Antagonist Carboperamide (MR 16155) Administration In Rats," Neuropsychopharmacology, 15(1):31-35 (1996).
M	C25	Murakami et al., "AQ-0145, A Newly Developed Histamine H ₃ Antagonist, Decreased Seizure Susceptibility Of Electrically Induced Convulsions In Mice," Meth. Find. Exp. Clin. Pharmacol. 17(C):70-73 (1995)
M	C26	Onodera et al., "Neuropharmacology Of The Histaminergic Neuron System In The Brain And Its Relationship With Behavioral Disorders," Progress In Neurobiology, 42:685-702 (1994).
M	C27	Panula et al., "Histamine Neurons in Human Hypothalamus: Anatomy in Normal and Alzheimer Diseased Brains," Neuroscience 44(2):465-481 (1991)
M	C28	Panula et al., "Neuronal Histamine Deficit in Alzheimer's Disease," Neuroscience 82(4):993-997 (1998)
M	C29	Perez-Garcia et al., "Effects Of Histamine H ₃ Receptor Ligands In Experimental Models Of Anxiety And Depression," Psychopharmacology 142:215-220 (1999)
M	C30	Phillips et al., "Recent Advances In Histamine H ₃ Receptor Agents," Annual Reports In Medicinal Chemistry, 33:31-40 (1998).
M	C31	Rouleau, "Bioavailability, Antinociceptive And Antiinflammatory Properties Of BP 2-94, A Histamine H ₃ Receptor Agonist Prodrug," The Journal Of Pharmacology And Experimental Therapeutics, 281(3):1085-1094 (1997).
M	C32	Sakai et al., "Effects Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Locomotor Activity And Brain Histamine Content In Mast Cell-Deficient W/W ^v Mice," Life Sciences, 48:2397-2404 (1991).
M	C33	Schwartz et al., "Histaminergic Transmission in the Mammalian Brain," Physiological Reviews 71(1):1-51 (1991)
M	C34	Schwartz et al., "Histamine," Psychopharmacology: The Fourth Generation Of Progress, 397-405 (1995).
M	C35	Shaywitz et al., "Dopaminergic But Not Noradrenergic Mediation Of Hyperactivity And Performance Deficits In The Developing Rat Pup," Psychopharmacology, 82:73-77 (1984).
M	C36	Szelag, "Role Of Histamine H ₃ -Receptors In The Proliferation Of Neoplastic Cells In Vitro," Med. Sci. Monit., 4(5):747-755 (1998).
M	C37	Tedford et al., "Cognition And Locomotor Activity In The Developing Rat: Comparisons Of Histamine H ₃ Receptor Antagonists And ADHD Therapeutics," Society For Neuroscience Abstr., 22:22 (1996).
M	C38	Tedford et al., "Pharmacological Characterization Of GT-2016, A Non-Thiourea-Containing Histamine H ₃ Receptor Antagonist: <i>In Vitro</i> And <i>In Vivo</i> Studies," The Journal Of Pharmacology And Experimental Therapeutics, 275(2):598-604 (1995).
M	C39	Wada et al., "Is The Histaminergic Neuron System A Regulatory Center For Whole-Brain Activity?," Trends In Neurosciences, 14(9):415-418 (1991).



C40	Yates et al., "Effects Of A Novel Histamine H ₃ Receptor Antagonist, GT-2394, On Food Intake And Weight Gain In Sprague-Dawley Rats," Abstracts, Society For Neuroscience, 102.10:219 (November 2000)
C41	Yokoyama et al., "Effect Of Thioperamide, A Histamine H ₃ Receptor Antagonist, On Electrically Induced Convulsions In Mice," Journal Of Pharmacology, 234:129-133 (1993).
C42	Yokoyama et al., "Histamine And Seizures Implications For The Treatment Of Epilepsy," CNS Drugs, 5(5):321-330 (1996).

EXAMINER

V. Balasubraman

DATE CONSIDERED

6/24/04

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)